早期可手术乳腺癌女性的术后放疗(苏格兰保乳试验):随机对照3期试验的30年更新
苏格兰保乳试验在14家医院纳入589例早期乳腺癌患者,随机分入放疗组与无放疗组,中位随访17.5年;放疗组同侧乳腺肿瘤复发显著低于无放疗组(HR 0.39),但两组总生存无差异(HR 1.08,p=0.43)。
要点
- 放疗组同侧乳腺肿瘤复发16% vs 无放疗组36%,HR 0.39(95%CI 0.28-0.55),p<0.0001。
- 治疗后的第一个十年内同侧复发风险HR 0.24,此后两组风险相似(HR 0.98,p=0.95)。
核心结论
- 作者认为,生物学特征预测保乳术后十年或更晚才出现晚期复发的早期乳腺癌患者,可能从辅助放疗中获益很少。
研究设计与样本
- 随机对照3期试验,在苏格兰14家医院纳入年龄小于70岁、肿瘤≤4 cm(T1或T2且N0或N1)的早期乳腺癌女性,行保乳手术(切缘1 cm)及腋窝淋巴结取样或清扫。
- 雌激素受体(ER)丰富患者(≥20 fmol/mg蛋白)接受口服他莫昔芬20 mg每日一次共5年;ER贫乏患者(<20 fmol/mg蛋白)接受环磷酰胺600 mg/m2、甲氨蝶呤50 mg/m2和氟尿嘧啶600 mg/m2每21天静脉给药共8个疗程的化疗。
- 按月经状态(距末次月经12个月以内或以上)和ER状态(雌激素浓度≥20 fmol/mg蛋白、<20 fmol/mg蛋白或未知)分层,1:1随机分配至高剂量(50 Gy分20-25次)局部或局部区域放疗组 versus 无放疗组,因治疗性质无法设盲。
- 1985年4月1日至1991年10月2日共589例患者入组并随机分配(放疗组293例,无放疗组296例);排除4例不合格患者(每组2例)后,放疗组291例,无放疗组294例。
- 主要终点为同侧乳腺肿瘤复发,共同主要终点为总生存;按意向性治疗分析,采用log-rank检验比较临床结局,风险比(HR)以无放疗组为参照组。
主要发现
- 中位随访17.5年(IQR 8.4-27.9)。
- 放疗组同侧乳腺肿瘤复发显著低于无放疗组:46例(16%)/291 vs 107例(36%)/294,HR 0.39(95%CI 0.28-0.55),p<0.0001。
- 治疗后第一个十年内同侧乳腺肿瘤复发风险HR 0.24(95%CI 0.15-0.38),p<0.0001;此后两组同侧复发风险相似,HR 0.98(95%CI 0.54-1.79),p=0.95。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Breast-conserving surgery, adjuvant systemic therapy, and radiotherapy are the standard of care for most women with early breast cancer. There are few reports of clinical outcomes beyond the first decade of follow-up of randomised trials comparing breast-conserving surgery with or without radiotherapy. We present a 30-year update of the Scottish Breast Conservation Trial. METHODS: In this randomised, controlled, phase 3 trial across 14 hospitals in Scotland, women aged younger than 70 years with early breast cancer (tumours ≤4 cm [T1 or T2 and N0 or N1]) were included. They underwent breast-conserving surgery (1 cm margin) with axillary node sampling or clearance. Oestrogen receptor (ER)-rich patients (≥20 fmol/mg protein) received 20 mg oral tamoxifen daily for 5 years. ER-poor patients (<20 fmol/mg protein) received chemotherapy (cyclophosphamide 600 mg/m2, methotrexate 50 mg/m2, and fluorouracil 600 mg/m2 every 21 days intravenously in eight courses). Stratification was by menstrual status (within or more than 12 months from last menstrual period) and ER status (oestrogen concentration ≥20 fmol/mg protein, <20 fmol/mg protein, or unknown) and patients were randomly assigned (1:1) to high-dose (50 Gy in 20-25 fractions) local or locoregional radiotherapy versus no radiotherapy. No blinding was possible due to the nature of the treatment. We report the primary endpoint of the original trial, ipsilateral breast tumour recurrence, and the co-primary endpoint, overall survival. Clinical outcomes were compared by the log-rank test. Hazard ratios (HRs) are reported, with no radiotherapy as the reference group. Failures of the proportional hazards assumption are reported if significant. All analyses are by intention to treat. FINDINGS: Between April 1, 1985, and Oct 2, 1991, 589 patients were enrolled and randomly assigned to the two treatment groups (293 to radiotherapy and 296 to no radiotherapy). After exclusion of four ineligible patients (two in each group), there were 291 patients in the radiotherapy group and 294 patients in the no radiotherapy group. Median follow-up was 17·5 years (IQR 8·4-27·9). Ipsilateral breast tumour recurrence was significantly lower in the radiotherapy group than in the no radiotherapy group (46 [16%] of 291 vs 107 [36%] of 294; HR 0·39 [95% CI 0·28-0·55], p<0·0001). Although there were differences in the hazard rate for ipsilateral breast tumour recurrence in the first decade after treatment (HR 0·24 [95% CI 0·15-0·38], p<0·0001), subsequent risks of ipsilateral breast tumour recurrence were similar in both groups (0·98 [0·54-1·79], p=0·95). There was no difference in overall survival between the two groups (median 18·7 years [95% CI 16·5-21·5] in the no radiotherapy group vs 19·2 years [16·9-21·3] in the radiotherapy group; HR 1·08 [95% CI 0·89-1 ·30], log-rank p=0·43). INTERPRETATION: Our findings suggest that patients whose biology predicts a late relapse a decade or more after breast-conserving surgery for early breast cancer might gain little from adjuvant radiotherapy. FUNDING: Breast Cancer Institute (part of Edinburgh and Lothian Health Foundation) and PFS Genomics (now part of Exact Sciences).
引用
- Williams LJ, Kunkler IH, Taylor KJ, et al. Postoperative radiotherapy in women with early operable breast cancer (Scottish Breast Conservation Trial): 30-year update of a randomised, controlled, phase 3 trial. Lancet Oncol. 2024. PMID: 39127062. doi:10.1016/S1470-2045(24)00347-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。